| metastatic-recurrent HNSCC (mHNSCC) | |||||
| mHNSCC - L1 - all population | mHNSCC - L1 - PDL1 positive | mHNSCC - L2 - all population | mHNSCC - L2 - PDL1 negative | mHNSCC - L2 - PDL1 positive | |
| immune chekpoint inhibitors | |||||
| anti-PD-(L)1 | |||||
| durvalumab based treatment | |||||
| durvalumab alone | EAGLE ... | ||||
| nivolumab based treatment | |||||
| nivolumab alone | CheckMate 141 | ||||
| pembrolizumab based treatment | |||||
| pembrolizumab alone | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... | KEYNOTE-040 ... | KEYNOTE-040 ... | |
| pembrolizumab plus 5FU plus platin | KEYNOTE-048 ... | KEYNOTE-048 ... KEYNOTE-048 ... | |||
| Immune checkpoint association | |||||
| durvalumab plus tremelimumab | EAGLE ... | CONDOR ... CONDOR ... | |||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
